论文部分内容阅读
让我们来看看下面的数据: 2002年,海王银河医药有限公司的营业额为7.2亿元人民币,亏损1100万,在国内药品批发企业中排名位居第39位; 2003年,公司营业额14.7亿,净利润1400万,在国内药品批发企业中排名位居第27位; 2004年,全年营业额26.1亿元,净利润3034万元,迅速由一个地市级的药品批发站发展成为居中国同行业前列的药品流通企业,在中国药品销售大省山东省已处于绝对的市场领导地位。 2005年,海王银河的计划目标是完成销售45亿元,力争50亿元,实现利税1亿元。海王银河在创造着业内高速增长的神话,被业界誉为“潍坊海王模式”。一年一大步,一步一台阶,这一切是如何实现的,本期“中国医药流通行业精英论坛”,我们邀请了海王银河的董事长孔宪俊讲述一个发展神话。
Let us look at the following data: In 2002, Neptune Galaxy Pharmaceutical Co., Ltd. turnover of 720 million yuan, a loss of 11 million in the domestic pharmaceutical wholesale enterprises ranked 39; 2003, the company turnover of 14.7 Billion, net profit of 14 million, ranking the 27th in the domestic pharmaceutical wholesale enterprises; in 2004, the annual turnover of 2.61 billion yuan, net profit of 30.34 million yuan, rapidly from a city-level drug wholesale station developed into a home The pharmaceutical distribution enterprises in the forefront of the industry in China are already in absolute market leadership in Shandong Province, a large pharmaceutical sales province in China. In 2005, the goal of Neptune Galaxy is to complete the sales of 4.5 billion yuan, strive to 5 billion yuan and realize profits and taxes of 100 million yuan. Neptune Galaxy to create the myth of rapid growth in the industry, the industry as the “Weifang Neptune model.” One big step a year, step by step, all this is how to achieve this issue, “China Pharmaceutical Circulation Industry Elite Forum”, we invited the chairman of the Galaxy Wang Xianghong Galaxy about a development of myth.